lungesoccer56
About
Resistant checkpoint inhibitors as well as anlotinib compared to anlotinib alone while third-line remedy in sophisticated non-small-cell carcinoma of the lung: a new retrospective research.
Resistant checkpoint inhibitors as well as anlotinib compared to anlotinib alone while third-line remedy in sophisticated non-small-cell carcinoma of the lung: a new retrospective research.